Dexcel Pharma Technologies Ltd.’s proposed generic will infringe US Patent Nos. 7,214,695, 7,214,696, and 9,770,441 if the asserted patent claims aren’t proven invalid, according to a stipulation and proposed order of infringement that Magistrate Judge Christopher J. Burke approved in the US District Court for the District of Delaware.
Such concessions are a common tactic that allows an accused ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.